3-(2-Methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(2-Methylpyrimidin-5-yl)-5-oxo-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid
• 化学式: C₂₂H₂₈N₄O₃
• 分子量: 396.5
• InChiKey: MMIMNHFTOYWLHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Compositions Methods for Treating Chronic Kidney Disease
  申请人：COX Jason M.

  公开号：US20180110762A1

  公开（公告）日：2018-04-26

  This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
• Composition and Methods for Treating Chronic Kidney Disease
  申请人：MERCK SHARP & DOHME CORP

  公开号：US20190307735A1

  公开（公告）日：2019-10-10

  This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
• US6410526B1
  申请人：——

  公开号：US6410526B1

  公开（公告）日：2002-06-25